Search
Sotatercept
go.drugbank.com/drugs/DB12118ApprovedInvestigationalSotatercept is an activin signalling inhibitor.
Erdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine is a drug that causes a breakdown of mucus, also known as a mucolytic agent. It is a thiol derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic br...
Alglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalAglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. It is encoded by the most predominant of nine observed haplotypes of this gene. Agluc...
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigationalAlmonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesInfluenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16917ApprovedUpon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Elesclomol
go.drugbank.com/drugs/DB05719InvestigationalIn preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal
Sea salt
go.drugbank.com/drugs/DB11266ApprovedUnlike sea salt, table salt usually contains an additive to prevent clumping and involves addition of iodine.
Products: Ruby Cell 4u Mud Moisture PureGuselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalIL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].
Emicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.
Clesrovimab
go.drugbank.com/drugs/DB18877Approvedpatients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed to provide passive immunization against RSV infection as an